This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Abstract Details
Activity Number:
|
78
|
Type:
|
Contributed
|
Date/Time:
|
Sunday, August 1, 2010 : 4:00 PM to 5:50 PM
|
Sponsor:
|
Section on Risk Analysis
|
Abstract - #309146 |
Title:
|
Updated Risk Assessment of Variant Creutzfeldt-Jakob Disease (vCJD) Risks for Recipients of Blood and Plasma-Derived Products in the United States
|
Author(s):
|
Steven Anderson*+ and Hong Yang and Richard Forshee and Mark Walderhaug
|
Companies:
|
FDA and FDA and FDA and FDA
|
Address:
|
1401 Rockville Pike, Rockville , MD, 20852,
|
Keywords:
|
Variant Creutzfeldt-Jakob disease ;
Blood ;
transfusion ;
hemophilia ;
Factor VIII ;
risk assessment
|
Abstract:
|
The identification of 4 cases of transfusion-transmitted vCJD (the human counterpart of 'mad cow' disease) and 1 case in a hemophiliac in the UK prompted the US FDA to re-evaluate vCJD risks for recipients of plasma-derived products in the US. Our updated risk assessment assumes all persons are equally susceptible to vCJD and estimates risk for plasma-derived Factor VIII (pdFVIII) recipients. For severe hemophilia patients at highest risk the model estimated annual mean exposure to be ~7 x 10-8 iv ID50 (~1 in 270,000) with the lower prevalence (4 per million) assumption, and ~1 x 10-4 iv ID50 (~1 in 12,000) with higher prevalence (1 per 4,225) assumption. Due to limited data and knowledge of vCJD, the model estimates are uncertain but suggest the risk is small, and donor deferral and manufacturing processes greatly reduce the risk.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2010 program
|
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.